Analysts’ Weekly Ratings Updates for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

• 10/21/2025 – Neurocrine Biosciences is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $175.00 price target on the stock.
• 10/20/2025 – Neurocrine Biosciences had its price target raised by analysts at Morgan Stanley from $163.00 to $168.00. They now have an “overweight” rating on the stock.
• 10/15/2025 – Neurocrine Biosciences was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/9/2025 – Neurocrine Biosciences had its price target raised by analysts at UBS Group AG from $188.00 to $195.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Neurocrine Biosciences had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Neurocrine Biosciences had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush.
• 9/22/2025 – Neurocrine Biosciences had its price target raised by analysts at Needham & Company LLC from $161.00 to $170.00. They now have a “buy” rating on the stock.
• 9/5/2025 – Neurocrine Biosciences had its price target raised by analysts at Royal Bank Of Canada from $144.00 to $149.00. They now have an “outperform” rating on the stock.
• 9/5/2025 – Neurocrine Biosciences had its price target raised by analysts at Morgan Stanley from $158.00 to $163.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the transaction, the director owned 514,596 shares in the company, valued at $65,050,080.36. This trade represents a 17.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.